JP2008536931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008536931A5 JP2008536931A5 JP2008507783A JP2008507783A JP2008536931A5 JP 2008536931 A5 JP2008536931 A5 JP 2008536931A5 JP 2008507783 A JP2008507783 A JP 2008507783A JP 2008507783 A JP2008507783 A JP 2008507783A JP 2008536931 A5 JP2008536931 A5 JP 2008536931A5
- Authority
- JP
- Japan
- Prior art keywords
- range
- weight percent
- present
- fluorobenzyl
- methanesulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 150000004682 monohydrates Chemical class 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims 3
- 239000008109 sodium starch glycolate Substances 0.000 claims 3
- 239000007917 core tablet composition Substances 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67280505P | 2005-04-19 | 2005-04-19 | |
| US60/672,805 | 2005-04-19 | ||
| PCT/US2006/014447 WO2006113649A1 (en) | 2005-04-19 | 2006-04-18 | Pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008536931A JP2008536931A (ja) | 2008-09-11 |
| JP2008536931A5 true JP2008536931A5 (enExample) | 2009-06-04 |
| JP5202302B2 JP5202302B2 (ja) | 2013-06-05 |
Family
ID=37115487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507783A Active JP5202302B2 (ja) | 2005-04-19 | 2006-04-18 | 医薬組成物 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8821927B2 (enExample) |
| EP (1) | EP1871347B1 (enExample) |
| JP (1) | JP5202302B2 (enExample) |
| KR (1) | KR101356748B1 (enExample) |
| CN (1) | CN101203211B (enExample) |
| AR (1) | AR054252A1 (enExample) |
| AU (1) | AU2006236423B2 (enExample) |
| BR (1) | BRPI0609962B1 (enExample) |
| CA (1) | CA2606207C (enExample) |
| CY (1) | CY1118179T1 (enExample) |
| DK (1) | DK1871347T3 (enExample) |
| EA (1) | EA200702253A1 (enExample) |
| ES (1) | ES2601503T3 (enExample) |
| HR (1) | HRP20161429T1 (enExample) |
| HU (1) | HUE030982T2 (enExample) |
| IL (1) | IL186336A0 (enExample) |
| LT (1) | LT1871347T (enExample) |
| MA (1) | MA29404B1 (enExample) |
| MX (1) | MX2007013089A (enExample) |
| NO (1) | NO20075111L (enExample) |
| NZ (1) | NZ562223A (enExample) |
| PE (1) | PE20061430A1 (enExample) |
| PL (1) | PL1871347T3 (enExample) |
| PT (1) | PT1871347T (enExample) |
| SI (1) | SI1871347T1 (enExample) |
| TW (1) | TW200716204A (enExample) |
| WO (1) | WO2006113649A1 (enExample) |
| ZA (1) | ZA200708705B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2606207C (en) * | 2005-04-19 | 2014-11-18 | Smithkline Beecham (Cork) Limited | Pharmaceutical composition |
| US8252805B2 (en) | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
| EP2158912A1 (en) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| EP2158913A1 (en) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| WO2010099150A1 (en) * | 2009-02-24 | 2010-09-02 | Smithkline Beecham (Cork) Limited | Pharmaceutical tablet and process |
| WO2011039759A1 (en) * | 2009-09-29 | 2011-04-07 | Natco Pharma Limited | A new process for the preparation of lapatinib and its pharmaceutically acceptable salts |
| US9180129B2 (en) | 2010-05-21 | 2015-11-10 | Novartis Ag | Combination of lapatinib and trametinib |
| JP2013526578A (ja) | 2010-05-21 | 2013-06-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| SG187689A1 (en) | 2010-08-03 | 2013-03-28 | Altherx Inc | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| EP2958552B1 (en) * | 2013-02-19 | 2017-06-21 | Hexal AG | Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof |
| WO2014170910A1 (en) | 2013-04-04 | 2014-10-23 | Natco Pharma Limited | Process for the preparation of lapatinib |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| EP3226849A4 (en) | 2014-12-03 | 2018-05-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| CN106389373B (zh) * | 2015-07-29 | 2019-07-02 | 四川科伦药物研究院有限公司 | 一种二甲苯磺酸拉帕替尼片剂及其制备方法 |
| CN106511289A (zh) * | 2015-09-10 | 2017-03-22 | 湖北生物医药产业技术研究院有限公司 | 甲苯磺酸拉帕替尼片剂及其制备方法 |
| US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| EP0977750B1 (en) | 1997-04-25 | 2007-07-04 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibiting quinazolinones |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| IL153111A0 (en) * | 2000-06-30 | 2003-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| DE60203260T2 (de) | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| US20050176740A1 (en) | 2002-04-08 | 2005-08-11 | Spector Neil L. | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| EP1810034A4 (en) | 2002-06-19 | 2008-06-25 | Smithkline Beecham Corp | PREDICTIVE MARKERS IN CANCER THERAPY |
| CA2606207C (en) * | 2005-04-19 | 2014-11-18 | Smithkline Beecham (Cork) Limited | Pharmaceutical composition |
-
2006
- 2006-04-18 CA CA2606207A patent/CA2606207C/en active Active
- 2006-04-18 MX MX2007013089A patent/MX2007013089A/es active IP Right Grant
- 2006-04-18 SI SI200632109A patent/SI1871347T1/sl unknown
- 2006-04-18 EA EA200702253A patent/EA200702253A1/ru unknown
- 2006-04-18 PT PT67504753T patent/PT1871347T/pt unknown
- 2006-04-18 HR HRP20161429TT patent/HRP20161429T1/hr unknown
- 2006-04-18 WO PCT/US2006/014447 patent/WO2006113649A1/en not_active Ceased
- 2006-04-18 AU AU2006236423A patent/AU2006236423B2/en not_active Revoked
- 2006-04-18 BR BRPI0609962-9A patent/BRPI0609962B1/pt active IP Right Grant
- 2006-04-18 HU HUE06750475A patent/HUE030982T2/en unknown
- 2006-04-18 ES ES06750475.3T patent/ES2601503T3/es active Active
- 2006-04-18 PL PL06750475T patent/PL1871347T3/pl unknown
- 2006-04-18 JP JP2008507783A patent/JP5202302B2/ja active Active
- 2006-04-18 KR KR1020077026740A patent/KR101356748B1/ko active Active
- 2006-04-18 DK DK06750475.3T patent/DK1871347T3/en active
- 2006-04-18 US US11/911,843 patent/US8821927B2/en active Active
- 2006-04-18 LT LTEP06750475.3T patent/LT1871347T/lt unknown
- 2006-04-18 EP EP06750475.3A patent/EP1871347B1/en active Active
- 2006-04-18 CN CN2006800219417A patent/CN101203211B/zh active Active
- 2006-04-18 TW TW095113811A patent/TW200716204A/zh unknown
- 2006-04-18 PE PE2006000406A patent/PE20061430A1/es not_active Application Discontinuation
- 2006-04-18 AR AR20060101526A patent/AR054252A1/es not_active Application Discontinuation
- 2006-04-18 NZ NZ562223A patent/NZ562223A/en not_active IP Right Cessation
-
2007
- 2007-10-07 IL IL186336A patent/IL186336A0/en unknown
- 2007-10-09 NO NO20075111A patent/NO20075111L/no not_active Application Discontinuation
- 2007-10-11 ZA ZA200708705A patent/ZA200708705B/xx unknown
- 2007-10-25 MA MA30318A patent/MA29404B1/fr unknown
-
2014
- 2014-07-28 US US14/444,637 patent/US20140335177A1/en not_active Abandoned
-
2016
- 2016-01-29 US US15/009,927 patent/US20160143909A1/en not_active Abandoned
- 2016-11-03 CY CY20161101115T patent/CY1118179T1/el unknown